# GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

> **NCT03845179** · NA · COMPLETED · sponsor: **University Hospital, Gentofte, Copenhagen** · enrollment: 12 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **OTHER:** Placebo
- **OTHER:** GIP receptor antagonist
- **DRUG:** DPP-4 inhibitor
- **OTHER:** Placebo tablet

## Key facts

- **NCT ID:** NCT03845179
- **Lead sponsor:** University Hospital, Gentofte, Copenhagen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-29
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03845179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03845179, "GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03845179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*